01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Open Orphan (ORPH) – CRUX Asset Management Ltd increase Holding(s) in Company October 1, 2019 – Posted in: Open Orphan (ORPH)

TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Open Orphan PLC 1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate…

Continue reading

Open Orphan (ORPH) Exercise of Warrants and Issue of Shares September 23, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that the Company has received notices of exercise of warrants over 539,654 ordinary shares of 0.1 pence each in the capital of the Company (“Ordinary Shares”) at a price of 0.1 pence per share for 191,051 ordinary shares and at a price of 2.2 pence per share for 348,603 ordinary shares. The gross proceeds of this exercise received by the Company amounts to…

Continue reading

Open Orphan (ORPH) Notice of AGM September 12, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that the Company’s Annual General Meeting will be held on 2 October 2019 at 12 noon at Jeffreys Henry LLP, Finsgate, 5-7 Cranwood Street, London EC1V 9EE. A copy of the notice of Annual General Meeting has been sent to shareholders and is available from the Company’s website.   Enquiries: Open Orphan Plc Tel: +353 (0)1 644 0007 Cathal Friel, Chief Executive Officer   Arden…

Continue reading

Open Orphan (ORPH) – Investor Event Attendance and Presentation September 3, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan presents at Shares Investor Evening, London Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at the Shares Investor Evening tomorrow from 18:00 at Novotel Hotel Tower Bridge, London, EC3N 2NR. Cathal Friel, Open Orphan’s Chief Executive Officer will be presenting from 18:30 onwards to update existing and potential investors on the Company’s business plans for 2019-2020. The event will provide an opportunity for…

Continue reading

Open Orphan (ORPH) Upcoming Investor Events September 2, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at a series of investor events from the 4thSeptember to 10th October 2019. Cathal Friel, Open Orphan’s Chief Executive Officer, will be in attendance for all of the events and will be presenting to update existing and potential investors on the Company’s business plans for 2019-2020. No new material information will be disclosed…

Continue reading

Orphan Drugs Market will be Gain at a Healthy CAGR of 12.10% by 2025 August 15, 2019 – Posted in: Open Orphan (ORPH)

Article by The Market Plan Region wise, the global orphan drug market is foretold to be predominantly held by North due to the presence of well-established medical infrastructure. Moreover, facilities like support by government in the drug development for rare diseases and rising awareness initiatives being taken by non-profit organization are expected to propel the growth in the global orphan drug market. The global orphan drug market is eminently competitive and fragmented in nature. There…

Continue reading